Sawyer & Company Inc Makes New Investment in Novo Nordisk A/S $NVO

Key Points

• Sawyer & Company acquired 44,287 Novo Nordisk shares during the third quarter, valued at approximately $1.68 million. Other major institutions, including Arrowstreet Capital, State Street and Renaissance Technologies, also hold or increased positions; institutional investors own 11.54% of the stock.
• Analyst sentiment remains cautious, with 16 Hold, five Buy and five Sell ratings and an average price target of $59.44. CFRA recently downgraded the stock to Sell with a $38 target, while shares traded near $39.27.
• Novo Nordisk’s outlook is mixed: promising CagriSema weight-loss results and expanded share buybacks support the investment case, but intensifying competition from Eli Lilly and Viking Therapeutics, pricing concerns and falling earnings estimates remain risks.

Sawyer & Company Inc purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 44,287 shares of the company's stock, valued at approximately $1,679,000.

A number of other institutional investors have also modified their holdings of the stock. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth about $287,660,000. State Street Corp lifted its holdings in Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company's stock valued at $284,565,000 after acquiring an additional 32,641 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company's stock valued at $193,250,000 after acquiring an additional 71,684 shares during the period. Royal Bank of Canada boosted its position in Novo Nordisk A/S by 3.2% in the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company's stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Novo Nordisk A/S by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company's stock worth $124,844,000 after purchasing an additional 213,443 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. Cfra cut shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 price objective on the stock. in a research note on Tuesday, September 22nd. Barclays reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. UBS Group restated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. BMO Capital Markets set a $40.00 price target on shares of Novo Nordisk A/S and gave the company a "market perform" rating in a research report on Monday, October 12th. Finally, Berenberg Bank reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $59.44.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema delivers strong weight-loss results: In a late-stage analysis, women with obesity or overweight lost an average of 25% of their body weight after 68 weeks. The result supports CagriSema as a potentially more effective successor to Wegovy and could strengthen Novo’s long-term position in the obesity-drug market. CNBC CagriSema analysis
• Positive Sentiment: Share repurchases provide support: Novo is expanding its 2026 buyback program, reportedly totaling DKK 15 billion, and has increased its treasury-share stake to about 1.2%. Buybacks can support per-share results and signal management’s confidence in the valuation. Novo Nordisk share buyback
• Neutral Sentiment: Investment outlook remains mixed: Analysts point to attractive valuation and continued investment in obesity and cardiometabolic treatments, including CagriSema regulatory submissions and a Prothena partnership, but the company’s future performance depends on commercialization, supply expansion and regulatory execution. Novo Nordisk obesity competition analysis
• Negative Sentiment: Competition and estimate pressure remain risks: Eli Lilly and Viking Therapeutics are intensifying competition in obesity drugs, while pricing, intellectual-property and regulatory concerns—including scrutiny of GLP-1-related supplements—could limit future growth. Declining earnings estimates have also tempered the positive reaction to CagriSema’s data. Novo Nordisk earnings estimates and valuation

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded down $0.07 during midday trading on Wednesday, reaching $39.27. The company had a trading volume of 3,203,936 shares, compared to its average volume of 16,668,912. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a market capitalization of $175.36 billion, a P/E ratio of 9.60, a P/E/G ratio of 1.30 and a beta of 0.76. The firm's fifty day simple moving average is $42.36 and its 200-day simple moving average is $43.99.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The business had revenue of $11.98 billion during the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.42 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were given a $0.5786 dividend. This represents a dividend yield of 258.0%. This is a negative change from Novo Nordisk A/S's previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 19.80%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.